



- (51) **International Patent Classification:**
C07K 14/145 (2006.01) *A61K 39/205* (2006.01)
- (21) **International Application Number:**
PCT/US2023/071904
- (22) **International Filing Date:**
09 August 2023 (09.08.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/371,148 11 August 2022 (11.08.2022) US
- (71) **Applicant:** ICOSAVAX, INC. [US/US]; 1930 Boren Avenue, Suite 1000, Seattle, WA 98101 (US).
- (72) **Inventors:** FELDHAUS, Andrew; c/o Icosavax, Inc., 1930 Boren Avenue, Suite 1000, Seattle, WA 98101 (US).
HOLTZMAN, Douglas; c/o Icosavax, Inc., 1930 Boren Avenue, Suite 1000, Seattle, WA 98101 (US).
- (74) **Agent:** AHN, Hye, Hyun et al.; Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** RABIES G PROTEIN AND USES THEREOF




FIG. 3

(57) **Abstract:** Provided are polypeptide comprising a rabies G protein ectodomain. The rabies G protein ectodomain may have a deletion of the fusion loop domain. Further provided are nanoparticle vaccines for rabies virus. Further provided are pharmaceutical compositions, methods of manufacturing, and methods of use, e.g, immunizing a subject to generate a protective immune response to rabies virus.

[Continued on next page]

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*